Document is current
Any future updates will be listed below
-
Authors
Pachynski, Russell K https://orcid.org/0000-0002-8966-7631
Morishima, Chihiro
Szmulewitz, Russell
Harshman, Lauren https://orcid.org/0000-0002-7636-1588
Appleman, Leonard
Monk, Paul
Bitting, Rhonda L
Kucuk, Omer
Millard, Frederick
Seigne, John D
Fling, Steven P
Maecker, Holden T
Duault, Caroline https://orcid.org/0000-0003-2742-1668
Ramchurren, Nirasha
Hess, Bruce
D’Amico, Leonard
Lacroix, Andreanne
Kaiser, Judith C
Morre, Michel
Grégoire, Anne
Cheever, Martin
Yu, Evan Y
Fong, Lawrence
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01881867 at ClinicalTrials.govnct00065442 at ClinicalTrials.govDocuments that mention this clinical trial
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-002903
Documents that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-012690
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-002903
-
Funding
Funding for this research was provided by:
RevImmune
Dendreon Corp.
National Cancer Institute (P30 CA015704)
National Cancer Institute (U01CA154967 and UM1CA154967)
- License Information
